Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes

Author:

Maddaloni Ernesto12ORCID,Coraggio Lucia1,Amendolara Rocco1,Baroni Marco G.3,Cavallo Maria G.1ORCID,Copetti Massimiliano4ORCID,Cossu Efisio5,D’Angelo Paola6,D’Onofrio Luca1ORCID,Cosmo Salvatore De4,Leonetti Frida1,Morano Susanna1,Morviducci Lelio7,Napoli Nicola8,Prudente Sabrina4,Pugliese Giuseppe1ORCID,Park Kyoungmin9,Holman Rury R.2,Trischitta Vincenzo14,Buzzetti Raffaella1ORCID,

Affiliation:

1. Sapienza University of Rome Rome Italy

2. Diabetes Trials Unit OCDEM University of Oxford Oxford UK

3. University of L’Aquila Rome Italy

4. Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo Rome Italy

5. Cagliari University Hospital Cagliari Italy

6. Sandro Pertini Hospital Rome Italy

7. Santo Spirito Hospital Rome Italy

8. Campus Bio‐Medico University Rome Italy

9. Joslin Diabetes Center Harvard Medical School Boston Massachusetts USA

Abstract

AbstractBackgroundNovel biomarkers of vascular disease in diabetes could help identify new mechanistic pathways. Osteocalcin, osteoprotegerin, and osteopontin are key molecules involved in bone and vascular calcification processes, both of which are compromised in diabetes. We aimed to evaluate possible associations of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease (CVD) and diabetic retinopathy (DR) among people with type 2 diabetes (T2D).Materials and MethodsOsteocalcin, osteoprotegerin, and osteopontin concentrations were measured at enrolment in 848 participants with T2D from the Sapienza University Mortality and Morbidity Event Rate (SUMMER) Study (ClinicalTrials.gov: NCT02311244). Logistic regression models and propensity score matching were used to assess possible associations of osteocalcin, osteoprotegerin, and osteopontin with a history of CVD and with evidence of any grade of DR adjusting for confounders.ResultsPrevious CVD was reported in 139 (16.4%) participants, while 144 (17.0%) had DR. After adjusting for possible confounders, osteocalcin but not osteoprotegerin or osteopontin concentrations were associated with a history of CVD (Odds Ratio [OR] and 95% CI for one standard deviation (SD) increase in osteocalcin concentrations (natural log): 1.35 (1.06–1.72), p = 0.014). Associations with prevalent DR were seen for osteoprotegerin (OR for one SD increase in osteoprotegerin concentrations (natural log): 1.25 (1.01–1.55), p = 0.047) and osteopontin (OR for one SD increase in osteopontin concentrations (natural log): 1.25 (1.02–1.53), p = 0.022), but not osteocalcin.ConclusionsIn T2D, higher serum osteocalcin concentrations are associated with macrovascular complications and higher osteoprotegerin and osteopontin concentrations with microvascular complications, suggesting that these osteokines might be involved in pathways directly related to vascular disease.

Funder

Sapienza Università di Roma

Ministero della Salute

European Foundation for the Study of Diabetes

Fondazione Diabete Ricerca

National Institute for Health Research

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3